References

ppan

Personalized Psychiatry and Neurology

2712-9179

V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)

10.52667/2712-9179-2023-3-2-72-119

ppan-87

Research Article

ARTICLE

Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders

Shnayder

N. A.

Natalia A. Shnayder

192019, Saint Petersburg

660022, Krasnoyarsk

naschnaider@yandex.ru

Kidyaeva

A. V.

Alla V. Kidyaeva

190121, Saint Petersburg

Vaiman

E. E.

Elena E. Vaiman

192019, Saint Petersburg

Asadullin

A. R.

Azat R. Asadullin

450008, Ufa

Petrova

M. M.

Marina M. Petrova

660022, Krasnoyarsk

Kaskaeva

D. S.

Daria S. Kaskaeva

660022, Krasnoyarsk

Matyushin

G. V.

Gennady V. Matyushin

660022, Krasnoyarsk

Evsyukov

A. A.

Aleksandr A. Evsyukov

660022, Krasnoyarsk

Galko

E. V.

Elena V. Galko

660058, Krasnoyarsk

Garganeeva

N. P.

Natalia P. Garganeeva

634050, Tomsk

Chumakova

G. A.

Galina A. Chumakova

656038, Barnaul

Lareva

N. V.

Natalia V. Lareva

672000, Chita

Neznanov

N. G.

Nikolai G. Neznanov

192019, Saint Petersburg

Nasyrova

R. F.

Regina F. Nasyrova

192019, Saint Petersburg

443016, Samara

Tel.: +7-(812)-620-02-20-78-13

regina_nmrcpn@mail.ru

V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityRussian FederationSt. Petersburg State Psychiatric Hospital of St. NicholasRussian FederationV.M. Bekhterev National Medical Research Centre for Psychiatry and NeurologyRussian FederationBashkir State Medical UniversityRussian FederationV.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityRussian FederationRussian Railways Medical ClinicRussian FederationSiberian State Medical UniversityRussian FederationAltai State Medical UniversityRussian FederationChita State Medical AcademyRussian FederationV.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; Samara State Medical UniversityRussian Federation

2023

15112023

3272119

Copyright © Shnayder N.A., Kidyaeva A.V., Vaiman E.E., Asadullin A.R., Petrova M.M., Kaskaeva D.S., Matyushin G.V., Evsyukov A.A., Galko E.V., Garganeeva N.P., Chumakova G.A., Lareva N.V., Neznanov N.G., Nasyrova R.F., 2023

2023

Shnayder N.A., Kidyaeva A.V., Vaiman E.E., Asadullin A.R., Petrova M.M., Kaskaeva D.S., Matyushin G.V., Evsyukov A.A., Galko E.V., Garganeeva N.P., Chumakova G.A., Lareva N.V., Neznanov N.G., Nasyrova R.F.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.jppn.ru/jour/article/view/87

Antidepressants (ADs) include drugs of various pharmacological groups, which are mainly used for the treatment of mental disorders (major depressive disorder, obsessive-compulsive disorder, social phobia, panic disorder, generalized anxiety disorder, post-traumatic stress disorder), chronic pain and addiction diseases. Chronic use of ADs can lead to the development of cardiotoxic adverse drug reactions (ADRs). The most important cardiotoxic AD-induced ADRs are prolongation of the QT interval, ventricular tachycardia of the "pirouette" type (Torsades de Pointes - TdP). This narrative review analyzes and summarizes the results of studies on pharmacokinecis and pharmacogenetics of ADs on QT interval prolongation and updates physicians' knowledge of the risk of developing AD-induced TdP in patients with psychiatric disorders.

antidepressantsafetyadverse drug reactionQT intervallong QT syndromerisk factorantidepressant-induced repolarization disorderTorsades de Pointessudden death syndrometreatment

References1

Alexandrovsky, Y.A.; Neznanov, N.G.; Mironova, N.V. Psychiatry: a national guide. 2nd edition, revised and enlarged. Moscow: Limited Liability Company Publishing Group "GEOTAR-Media", 2018, 976. ISBN 978-5-9704-4462-7.

Sheffler, Z.M.; Patel, P.; Abdijadid, S. Antidepressants. [Updated 2023 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Accessed June 15, 2023]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538182/

Jennings, L. Antidepressants. In: Grossberg, G., Kinsella, L. (eds) Clinical Psychopharmacology for Neurologists. Springer, Cham. 2018, 45-71. https://doi.org/10.1007/978-3-319-74604-3_4.

Pratt, L.A.; Brody, D.J.; Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011-2014. NCHS Data Brief. 2017, 283, 1-8. PMID: 29155679.

Moore, T.J.; Mattison D.R. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med. 2017, 177(2), 274–275. https://doi.org/10.1001/jamainternmed.2016.7507.

Jakobsen, J.C.; Gluud, C.; Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evidence-Based Medicine 2020, 25, 130–136. https://doi.org/10.1136/bmjebm-2019-111238.

InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Treatments for depression. [Updated 2020 Jun 18]. [Accessed June 15, 2023]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279282/

Molenaar, N.M.; Kamperman, A.M.; Boyce, P.; Bergink, V. Guidelines on treatment of perinatal depression with antidepressants: An international review. Australian & New Zealand Journal of Psychiatry 2018, 52(4), 320-327. https://doi.org/10.1177/0004867418762057.

Litvinenko, T.S.; Safronenko, A.V.; Gantsgorn, E.V.; Kudelina, O.M.; Postnikova, E.S.; Chotiy, V.A. Adverse drug reactions and methodological approaches to their monitoring. Journal Biomed. 2021, 17(3), 56-61. https://doi.org/10.33647/2074-5982-17-3-56-61.

Alomar, M.; Tawfiq, A.M.; Hassan, N.; Palaian, S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020, 10, 11. https://doi.org/10.1177/2042098620938595.

Coleman, J.J.; Pontefract, S.K. Adverse drug reactions. Clin Med (Lond). 2016, 16(5), 481-485. https://doi.org/10.7861/clinmedi-cine.16-5-481.

Shakib, S.; Caughey, G.E.; Fok, J.S.; Smith, W.B. Adverse drug reaction classification by health professionals: appropriate discrimination between allergy and intolerance? Clin Transl Allergy 2019, 9, 18. https://doi.org/10.1186/s13601-019-0259-6.

Fda.gov [Internet]. What is a serious adverse event? [Updated 2023 Jun 10]. [Accessed June 15, 2023]. Available at: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event.

Li, M.; Ramos, L.G. Drug-induced QT prolongation and Torsades de Pointes. P T. 2017, 42(7), 473-477. PMID: 28674475.

Ostroumova, O.D.; Goloborodova, I.V. Drug-induced long QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum 2019, 21(5), 62–67. https://doi.org/10.26442/20751753.2019.5.190415.

Chernova, A.A. The syndrome of elongated QT interval. Siberian Medical Review 2012, 3 (75), 91-95.

Khatib, R.; Sabir, F.R.N; Omari, C.; Pepper, C.; Tayebjee, M.H. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021, 97(1149), 452-458. https://doi.org/10.1136/postgradmedj-2020-138661.

Li, Y.; Li, P.; Wang, X; Karmakar, C.; Liu, C.; Liu, C. Short-term QT interval variability in patients with coronary artery disease and congestive heart failure: A comparison with healthy control subjects. Med Biol Eng Comput. 2019, 57, 389–400. https://doi.org/10.1007/s11517-018-1870-8.

Zhuravlev, N.M.; Shnayder, N.A.; Vaiman, E.E.; Abdyrakhmanova, A.K.; Petrova, M.M.; Bochanova, E.N.; Romanova, I.V.; Gav-ilyuk, O.A.; Lareva, N.V.; Nasyrova, R.F. Interindividual variability of anticonvulsant-induced QT prolongation risk. Personalized Psychiatry and Neurology 2022, 2(1), 22–45. https://doi.org/10.52667/2712-9179-2022-2-1-23-45.

Vandenberk, B.; Vandael, E.; Robyns, T.; Vandenberghe, J.; Garweg, C.; Foulon, V; Ector, J.; Willems, R. Which QT Correction formulae to use for QT monitoring? J Am Heart Assoc. 2016, 5(6), e003264. https://doi.org/10.1161/JAHA.116.003264. Erratum in: J Am Heart Assoc. 2018, 7(16), e004252. https://doi.org/10.1161/JAHA.116.003264.

Rubricator of clinical recommendations [Accessed June 20, 2023]. Available at: https://cr.minzdrav.gov.ru/schema/569_1#doc_a2.

FDA Guidance for Industry E14 (2017) Clinical evaluation of QT/QTc interval prolongation for non-antiarrhythmic drugs—questions and answers (R3). [Accessed June 20, 2023]. Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs gen/documents/document/ucm073161.pdf.

Aktürk, G.; Kalkan, Ş. Drug-induced QT interval prolongation: mechanisms, risk factors, genetics and clinical management. Journal of Basic and Clinical Health Sciences 2019, 3 (3), 193-198. https://doi.org/10.30621/jbachs.2019.712.

Christensen, L.; Turner, J.R.; Peterson, G.M.; Naunton, M.; Thomas, J.; Yee, K.C.; Kosari, S. Identification of risk of QT prolongation by pharmacists when conducting medication reviews in residential aged care settings: a missed opportunity? J Clin Med. 2019, 8(11), 1866. https://doi.org/10.3390/jcm8111866.

Heemskerk, C.P.M.; Pereboom, M.; van Stralen, K.; Berger, F.A.; van den Bemt, P.M.L.A; Kuijper, A.F.M.; van der Hoeven, R.T.M.; Mantel-Teeuwisse, A.K.; Becker, M.L. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018, 74(2), 183-191. https://doi.org/10.1007/s00228-017-2381-5.

Sedlak, Т.; Shufelt, C.; Iribarren, C.; Merz, C.N.B. Sex hormones and the QT interval: a review. Journal of Women's Health 2012, 933-941. http://doi.org/10.1089/jwh.2011.3444.

Turner, J.R.; Rodriguez, I.; Mantovani, E.; Gintant, G.; Kowey, P.R.; Klotzbaugh, R.J.; Prasad, K.; Sager, P.T.; Stockbridge, N.; Strnadova, C.; Cardiac Safety Research Consortium. Drug-induced proarrhythmia and Torsade de Pointes: a primer for students and practitioners of medicine and pharmacy. J Clin Pharmacol. 2018, 58(8), 997-1012. https://doi.org/10.1002/jcph.1129.

Vaiman, E.E.; Shnayder, N.A.; Zhuravlev, N.M.; Petrova, M.M.; Asadullin, A.R.; Al-Zamil, M.; Garganeeva, N.P.; Shipulin, G.A.; Cumming, P.; Nasyrova, R.F. Genetic biomarkers of antipsychotic-induced prolongation of the QT interval in patients with schizophrenia. Int J Mol Sci. 2022, 23(24), 15786. https://doi.org/10.3390/ijms232415786.

Shlaykhtina, N.V.; Shabalin, A.V.; Yakhontov, D.A. Significance of increase in QT interval variance and changes in indicators of heart rhythm turbulence for estimation of risk of ventricular arrythmia development during the ethanol intoxication. Siberian Medical Review 2009, 3 (57), 31-33.

Tisdale, J.E. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016, 149(3), 139-52. https://doi.org/10.1177/1715163516641136.

Tolstikova, T.V.; Bregel, L.V.; Czurkan, S.V.; Marchuk, T.P.; Dudnik, A.V. Jervell and Lange-Nielsen syndrome. Family case (clinical observation). Siberian Medical Review 2020, 5 (125), 88-92. https://doi.org/10.20333/2500136-2020-5-88-92.

Beach, S.R.; Celano, C.M.; Noseworthy, P.A.; Januzzi, J.L.; Huffman, J.C. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013, 54(1), 1-13. https://doi.org/10.1016/j.psym.2012.11.001.

Stoetzer, C.; Papenberg, B.; Doll, T.; Völker, M.; Heineke, J.; Stoetzer, M.; Wegner F.; Leffler, A. Differential inhibition of cardiac and neuronal Na+ channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine. European Journal of Pharmacology 2016, 783, 1–10. https://doi.org/10.1016/j.ejphar.2016.04.051.

Drew, B.J.; Ackerman, M.J.; Funk, M.; Gibler, W.B.; Kligfield, P.; Menon, V.; Philippides, G.J.; Roden, D.M.; Zareba, W.; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; the Council on Cardiovascular Nursing; the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010, 121(8), 1047-60. https://doi.org/10.1161/CIRCULATIONAHA.109.192704.

Duncan, R.S.; McPate, M.J.; Ridley, J.M.; Gao, Z.; James, A.F.; Leishman, D.J.; Leaney, J.L.; Witchel, H.J.; Hancox, J.C. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol. 2007, 74(3), 425-437. https://doi.org/10.1016/j.bcp.2007.04.024.

Baxter, K.; Preston, C.L. Stockley’s drug interactions. London: Pharmaceutical Press. [Accessed June 22, 2023]. Available at: http://www.new.medicinescomplete.com.

Rochester, M.P.; Kane, A.M.; Linnebur, S.A.; Fixen, D.R. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Ther Adv Drug Saf. 2018, 9(6), 297-308. https://doi.org/10.1177/2042098618772979.

Cantet, G.; Berges, A.; O'Sullivan, R.; Cohen-Rabbie, S.; Dota, C.; Dubois, V.; Benoist, G.E.; Tomkinson, H.; Rekić, D.; Parkinson, J.; Schalkwijk, S. Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance. Br J Clin Pharmacol. 2022, 88(3), 1010-1019. https://doi.org/10.1111/bcp.15047.

Jackobson, G.; Carmel, N.N.; Lotan, D.; Kremer, A.; Justo, D. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsades de pointes. Z Gerontol Geriatr 2018; 51, 41-7. https://doi.org/10.1007/s00391-016-1155-5.

Schachtele, S.; Tumena, T.; Gassmann, K.G.; Fromm, M.F.; Maas, R. Co-prescription of QT-interval prolonging drugs: an analysis in a large cohort of geriatric patients. PloS One 2016, 11(5): e0155649. https://doi.org/10.1371/journal.pone.0155649.

Roden, D.M. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol. 2016, 594, 2459–68. https://doi.org/10.1113/JP270526.

Yap, Y.G.; Camm, A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89(11), 1363-72. https://doi.org/10.1136/heart.89.11.1363.

Danielsson, B.; Collin, J.; Nyman, A.; Bergendal, A.; Borg, N.; State, M.; Bergfeldt, L.; Fastbom, J. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study. BMJ Open 2020, 10(3), e034560. https://doi.org/10.1136/bmjopen-2019-034560.

Iribarren, C.; Round, A.D.; Peng, J.A.; Lu, M.; Zaroff, J.G.; Holve, T.J.; Prasad, A.; Stang, P. Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study. Pharmacoepidemiol Drug Saf. 2013, 22(11), 1222-1232. https://doi.org/10.1002/pds.3479.

Wong, J.; Motulsky, A.; Abrahamowicz, M.; Eguale, T.; Buckeridge, D.L.; Tamblyn, R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017, 356, j603. https://doi.org/10.1136/bmj.j603.

Schröder, C.; Dörks, M.; Kollhorst, B.; Blenk, T.; Dittmann, R.W.; Garbe, E.; Riedel, O. Outpatient antidepressant drug use in children and adolescents in Germany between 2004 and 2011. Pharmacoepidemiol Drug Saf. 2017, 26, 170-9. https://doi.org/10.1002/pds.4138.

Khasanova, A.K.; Nasyrova, R.F. Pharmacogenetic testing of cytochrome P450 system enzymes in the therapy of bipolar affective disorder. Personalized Psychiatry and Neurology 2022, 2(2), 90-96. https://doi.org/10.52667/2712-9179-2022-2-2-90-96.

Strelnik, A.I.; Romanov, D.V.; Strelnik, S.N. Generalized anxiety disorder therapy, associated with pronounced side effects, and prospects for the use of pharmacogenetic testing: case report. Personalized Psychiatry and Neurology 2023, 3(1), 59-65. https://doi.org/10.52667/2712-9179-2023-3-1-59-65.

Woosley, R.L.; Romero, K.A. QT Drugs Lists (registration required) [Accessed June 30, 2023]. Available at: www.CredibleMeds.org.

Heemskerk, C.P.M.; Pereboom, M.; van Stralen, K.; Berger, F.A.; van den Bemt, P.M.L.A.; Kuijper, A.F.M.; van der Hoeven, R.T.M.; Mantel-Teeuwisse, A.K.; Becker, M.L. Risk factors for QTc interval prolongation. Eur J.Clin Pharmacol. 2018, 74, 183–191. https://doi.org/10.1007/s00228-017-2381-5.

Vandael, E.; Vandenberk, B.; Vandenberghe, J.; Willems, R.; Foulon, V. Risk factors for QTc-prolongation: Systematic review of the evidence. Int J Clin Pharm. 2017, 39, 16–25. https://doi.org/10.1007/s11096-016-0414-2.

Hefner, G.; Hahn, M.; Hohner, M.; Roll, S.C.; Klimke, A.; Hiemke, C. QTc Time correlates with amitriptyline and venlafaxine serum levels in elderly psychiatric inpatients. Pharmacopsychiatry 2019, 52(1), 38-43. https://doi.org/10.1055/s-0044-102009.

Roden, D.M. Drug-induced prolongation of the QT interval. N Engl J Med. 2004, 350(10), 1013-22. https://doi.org/10.1056/NEJMra032426.

Tisdale, J.E.; Jaynes, H.A.; Kingery, J.R.; Mourad, N.A.; Trujillo, T.N.; Overholser, B.R.; Kovacs, R.J. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013, 6(4), 479-87. https://doi.org/10.1161/CIRCOUTCOMES.113.000152.

Novitsky, M.A.; De Suosa, A.; Asadullin, A.R.; Gavrilyuk, O.A.; Petrov, A.V.; Nasyrova, R.F. Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia. Personalized Psychiatry and Neurology 2021, 1(2), 21-45. https://doi.org/

Tripathi, A.C.; Upadhyay, S.; Paliwal, S.; Saraf, S.K. Privileged scaffolds as MAO inhibitors: Retrospect and prospects. European Journal of Medicinal Chemistry 2018, 145, 445–497. https://doi.org/10.1016/j.ejmech.2018.01.003.

State Register of Medicines [Accessed June 30, 2023]. Available at: https://grls.rosminzdrav.ru/Default.aspx.

Danilov, D.S. A 70-year history of tricyclic antidepressants. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2019, 119(12), 115-123. https://doi.org/10.17116/jnevro2019119121115.

Fasipe, O.J. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019, 6, 95-110. https://doi.org/10.1016/j.ibror.2019.01.001.

Yekehtaz, H.; Farokhnia, M.; Akhondzadeh, S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013, 8(4), 169-76. PMID: 26005484.

Noordam, R.; Sitlani, C.M.; Avery, C.L.; Stewart, J.D.; Gogarten, S.M.; Wiggins, K.L.; Trompet, S.; Warren, H.R.; Sun, F.; Evans, D.S.; Li, X.; Li, J.; Smith, A.V.; Bis, J.C.; Brody, J.A.; Busch, E.L.; Caulfield, M.J.; Chen, Y.I.; Cummings, S.R.; Cupples, L.A.; Duan, Q.; Franco, O.H.; Méndez-Giráldez, R.; Harris, T.B.; Heckbert, S.R.; van Heemst, D.; Hofman, A.; Floyd, J.S.; Kors, J.A.; Launer, L.J.; Li, Y.; Li-Gao, R.; Lange, L.A.; Lin, H.J.; de Mutsert, R.; Napier, M.D.; Newton-Cheh, C.; Poulter, N.; Reiner, A.P.; Rice, K.M.; Roach, J.; Rodriguez, C.J.; Rosendaal, F.R.; Sattar, N.; Sever, P.; Seyerle, A.A.; Slagboom, P.E.; Soliman, E.Z.; Sotoodehnia, N.; Stott, D.J.; Stürmer, T.; Taylor, K.D.; Thornton, T.A.; Uitterlinden, A.G.; Wilhelmsen, K.C.; Wilson, J.G.; Gudnason, V.; Jukema, J.W.; Laurie, C.C.; Liu, Y.; Mook-Kanamori, D.O.; Munroe, P.B.; Rotter, J.I.; Vasan, R.S.; Psaty, B.M.; Stricker, B.H.; Whitsel, E.A. A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. J Med Genet. 2017, 54(5), 313-323. https://doi.org/10.1136/jmedgenet-2016-104112.

Alvano, S.A.; Zieher, L.M. An updated classification of antidepressants: A proposal to simplify treatment. Personalized Medicine in Psychiatry 2019, 19–20. https://doi.org/10.1016/j.pmip.2019.04.002.

Fasipe, O.J.; Akhideno, P.E.; Owhin, O.S.; Ibiyemi-Fasipe, O.B. Announcing the first novel class of rapid-onset antidepressants in clinical practice. Journal of Medical Sciences 2019, 39(5), 205-216. https://doi.org/10.4103/jmedsci.jmedsci_36_19.

Nachimuthu, S.; Assar, M.D.; Schussler, J.M. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012, 3(5), 241-53. https://doi.org/10.1177/2042098612454283.

Eroglu, T.E.; Barcella, C.A.; Gerds, T.A.; Kessing, L.V.; Zylyftari, N.; Mohr, G.H.; Kragholm, K.; Polcwiartek, C.; Wissenberg, M.; Folke, F.; Hanno, L.T.; Torp-Pedersen, C.; Gislason, G.H. Risk of out-of-hospital cardiac arrest in antidepressant drug users. Br J Clin Pharmacol. 2022, 88, 3162–3171. https://doi.org/10.1111/bcp.15224.

Wilson, M.; Tripp, J. Clomipramine. [Updated 2021 Jan 26]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing 2021 Jan. [Accessed June 26, 2023]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK541006. PMID: 31082050.

Villatoro-Gómez, K.; Pacheco-Rojas, D.O.; Moreno-Galindo, E.G.; Navarro-Polanco, R.A.; Tristani-Firouzi, M.; Gazgalis, D.; Cui, M.; Sánchez-Chapula, J.A.; Ferrer, T. Molecular determinants of Kv7.1/KCNE1 channel inhibition by amitriptyline. Biochem Pharmacol. 2018, 152, 264-271. https://doi.org/10.1016/j.bcp.2018.03.016.

Zemrak, W.R.; Kenna, G.A. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008, 65(11), 1029-38. https://doi.org/10.2146/ajhp070279.

Shubin, D.Yu.; Kechemaykina, M.I.; Kiryukhina, S.V.; Labunsky, D.A. Features of the dynamics of some hematological and bio-chemical blood parameters during coronavirus infection in patients with mental disorders. Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders] 2023, 2, 2–9. https://doi.org/10.21265/PSYPH.2023.47.96.001.

Nosè, M.; Barbui, C. Do antidepressants prolong the QT interval? Epidemiol Psychiatr Sci. 2014, 23(1), 19-20. https://doi.org/10.1017/S204579601300070X.

Campleman, S.L.; Brent, J.; Pizon, A.F.; Shulman, J.; Wax, P.; Manini, A.F. Drug-specific risk of severe QT prolongation following acute drug overdose. Clin Toxicol (Phila). 2020, 58(12), 1326–1334. https://doi.org/10.1080/15563650.2020.1746330.

Funai, Y.; Funao, T.; Ikenaga, K.; Takahashi, R.; Hase, I.; Nishikawa, K. Use of tricyclic antidepressants as analgesic adjuvants results in nonhazardous prolongation of the QTc interval. Osaka City Med J. 2014, 60(1), 11-9. PMID: 25272563.

Okayasu, H.; Ozeki, Y.; Fujii, K.; Takano, Y.; Shinozaki, T.; Ohrui, M.; Shimoda, K. Investigation of the Proarrhythmic Effects of Antidepressants according to QT interval, QT dispersion and T wave peak-to-end interval in the clinical setting. Psychiatry Investig. 2019, 16(2), 159-166. https://doi.org/10.30773/pi.2018.12.11.

Noordam, R.; van den Berg, M.E.; Niemeijer, M.N.; Aarts, N.; Leening, M.J.; Deckers, J.W.; Hofman, A.; Rijnbeek, P.R.; Eijgelsheim, M.; Kors, J.A.; Stricker, B.H.; Visser, L.E. Assessing prolongation of the heart rate corrected QT interval in users of tricyclic antidepressants: advice to use Fridericia rather than Bazett's correction. J Clin Psychopharmacol. 2015, 35(3), 260-5. https://doi.org/10.1097/JCP.0000000000000321.

Rodríguez-Leal, C.M.; López-Lunar, E.; Carrascosa-Bernáldez, J.M.; Provencio-Arranz, R.M. Electrocardiographic surveillance in a psychiatric institution: avoiding iatrogenic cardiovascular death. Int J Psychiatry Clin Pract. 2017, 21(1), 64-66. https://doi.org/10.1080/13651501.2016.1234623.

Liu, M.; Yang, K.C.; Dudley, S. Cardiac sodium channel mutations: why so many phenotypes?. Nat Rev Cardiol. 2014, 11, 607–615. https://doi.org/10.1038/nrcardio.2014.85.

Elsayed, M.; Abdel-Kahaar, E.; Gahr, M.; Connemann, B.J.; Denkinger, M.; Schönfeldt-Lecuona, C. Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. Eur J Clin Pharmacol. 2021, 77(5), 767-775. https://doi.org/10.1007/s00228-020-03049-x.

Aronow, W.S.; Shamliyan, T.A. Effects of antidepressants on QT interval in people with mental disorders. Arch Med Sci. 2020, 16(4), 727-741. https://doi.org/10.5114/aoms.2019.86928.

Lubna, N.J.; Wada, T.; Nakamura, Y.; Chiba, K.; Cao, X.; Izumi-Nakaseko, H.; Ando, K.; Naito, A.T.; Satoh, Y.; Sugiyama, A. Amitriptyline may have possibility to induce Brugada syndrome rather than long QT syndrome. Cardiovasc Toxicol. 2018, 18(1), 91-98. https://doi.org/10.1007/s12012-017-9417-z.

Ryan, K.; Benz, P.; Zosel, A.; Farkas, A.; Theobald, J. QTc prolongation in Poison Center Exposures to CredibleMeds List of substances with "Known risk of Torsades de Pointes". Cardiovasc Toxicol. 2022, 22(9), 866-877. https://doi.org/10.1007/s12012-022-09764-4.

Sahin, O.; Akturk, G.; Cilaker, M.S.; Gursoy, D.O.; Karapinar, F.; Hocaoglu, N.; Ergur, B.U.; Akan, P.; Tuncok, Y.; Kalkan, S. Effect of the selective mitochondrial KATP channel opener nicorandil on the QT prolongation and myocardial damage induced by amitriptyline in rats. J Pharm Pharmacol. 2023, 75(3), 415-426. https://doi.org/10.1093/jpp/rgac089.

Barış, V.Ö.; Gedikli, E.; Dinçsoy, A.B.; Erdem, A. Empagliflozin significantly prevents QTc prolongation due to amitriptyline intoxication. Cardiovasc J Afr. 2023, 34, 1-5. https://doi.org/10.5830/CVJA-2023-017.

Basol, N.; Aygun, H.; Gul, S.S. Beneficial effects of edaravone in experimental model of amitriptyline-induced cardiotoxicity in rats. Naunyn Schmiedebergs Arch Pharmacol. 2019, 392(11), 1447-1453. https://doi.org/10.1007/s00210-019-01683-6.

Sorodoc, V.; Sorodoc, L.; Ungureanu, D.; Sava, A.; Jaba, I.M. Cardiac troponin T and NT-proBNP as biomarkers of early myocardial damage in amitriptyline-induced cardiovascular toxicity in rats. Int J Toxicol. 2013, 32(5), 351-7. https://doi.org/10.1177/1091581813503888.

Aygun, H.; Basol, N.; Gul, S.S. Cardioprotective effect of paricalcitol on amitriptyline-induced cardiotoxicity in rats: comparison of [99mTc]PYP cardiac scintigraphy with electrocardiographic and biochemical findings. Cardiovasc Toxicol. 2020, 20(4), 427-436. https://doi.org/10.1007/s12012-020-09569-3.

Unterecker, S.; Pfuhlmann, B.; Kopf, J.; Kittel-Schneider, S.; Reif, A.; Deckert, J. Increase of heart rate and QTc by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol. 2015, 35(4), 460-3. https://doi.org/10.1097/JCP.0000000000000336.

Ivanov, S.V.; Voronova, E.I. Depression therapy for somatic diseases. S.S. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry] 2021, 121(5), 106–112. https://doi.org/10.17116/jnevro2021121052106

Nussbaumer-Streit, B.; Thaler, K.; Chapman, A.; Probst, T.; Winkler, D.; Sönnichsen, A.; Gaynes, B.N.; Gartlehner, G. Second-generation antidepressants for treatment of seasonal affective disorder. The Cochrane Database of Systematic Reviews 2021, 3. https://doi.org/10.1002/14651858.CD008591.pub3.

Verbenko, V.; Dvirsky, A. The SSRI antidepressants: clinical aspects, new side effects and mechanisms of actions. Psikhiatriya. 2018, 1(77), 123-133. https://doi.org/2618-6667-2018-77-123-133.

Edinoff, A.N.; Akuly, H.A.; Hanna, T.A.; Ochoa, C.O.; Patti, S.J.; Ghaffar, Y.A.; Kaye, A.D.; Viswanath, O.; Urits, I.; Boyer, A.G.; Cornett, E.M.; Kaye, A.M. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurology International 2021, 13(3), 387-401. https://doi.org/10.3390/neurolint13030038.

Assimon, M.M.; Brookhart, M.A.; Flythe, J.E. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. J Am Soc Nephrol. 2019, 30(4), 611-623. https://doi.org/10.1681/ASN.2018101032.

Plijter, I.S.; Verkerk, A.O.; Wilders, R. The Antidepressant paroxetine reduces the cardiac sodium current. Int J Mol Sci. 2023, 24(3), 1904. https://doi.org/10.3390/ijms24031904.

Zivin, K.; Pfeiffer, P.N.; Bohnert, A.S.B.; Ganoczy, D.; Blow, F.C.; Nallamothu, B.K.; Kales, H.C. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. American Journal of Psychiatry 2013, 170(6), 642–650. https://doi.org/10.1176/appi.ajp.2013.12030408.

Straley, C.M.; Sochacki, M.; Reed, E.; Carr, C.N.; Baugh, T.B. Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: A cross-sectional study. J Affect Disord. 2022, 296, 476-484. https://doi.org/10.1016/j.jad.2021.08.149.

Otsuka, Y. Paroxetine-induced QTc prolongation. J Gen Fam Med. 2017, 18(6), 442-445. https://doi.org/10.1002/jgf2.137.

Maljuric, N.M.; Noordam, R.; Aarts, N.; Niemeijer, M.N.; van den Berg, M.E.; Hofman, A.; Kors, J.A.; Stricker, B.H.; Visser, L.E. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. Br J Clin Pharmacol. 2015, 80(4), 698-705. https://doi.org/10.1111/bcp.12681.

van Haelst, I.M.; van Klei, W.A.; Doodeman, H.J.; Warnier, M.J.; De Bruin, M.L.; Kalkman, C.J.; Egberts, T.C. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study. J Clin Psychiatry 2014, 75(1), 15-21. https://doi.org/10.4088/JCP.13m08397.

Ojero-Senard, A.; Benevent, J.; Bondon-Guitton, E.; Durrieu, G.; Chebane, L.; Araujo, M.; Montastruc, F.; Montastruc, J.L. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl). 2017, 234(20), 3075-3081. https://doi.org/10.1007/s00213-017-4685-7.

Ott, W.P.; Bellamy, S.E.; Khan, M.; Shahid, A.; Javed, M.T. Acquired long QT syndrome: ventricular fibrillation in an otherwise healthy young female. Cureus 2023, 15(4), e37263. https://doi.org/10.7759/cureus.37263.

100

Straley, C.M.; Sochacki, M.; Reed, E.; Carr, C.N.; Baugh, T.B. Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: a cross-sectional study. Journal of Affective Disorders 2021, https://doi.org/10.1016/j.jad.2021.08.149.

101

Funk, K.A.; Bostwick, J.R. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013, 47(10), 1330-41. https://doi.org/10.1177/1060028013501994.

102

Abbas, R.; Riley, S.; LaBadie, R.R.; Bachinsky, M.; Chappell, P.B.; Crownover, P.H.; Damle, B. A thorough QT study to evaluate the effects of a supratherapeutic dose of sertraline on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev. 2020, 9(3), 307-320. https://doi.org/10.1002/cpdd.749.

103

U.S. Food and Drug Administration. Abnormal heart arrhythmias associated with high foses of Celexa (citalopram hydrobromide). FDA Safety Communication 2011 [Accessed June 26, 2023]. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm269086.htm#data.

104

U.S. Food and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hy-drobromide) related to a potential risk of abnormal heart rhythms with high doses. Drug Safety and Availability 2012; [Accessed June 26, 2023]. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.

105

Coupland, C.; Hill, T.; Morriss, R.; Moore, M.; Arthur, A.; Hippisley-Cox, J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016, 352, i1350 https://doi.org/10.1136/bmj.i1350.

106

Drye, L.T.; Spragg, D.; Devanand, D.P.; Frangakis, C.; Marano, C.; Meinert, C.L.; Mintzer, J.E.; Munro, C.A.; Pelton, G.; Pollock, B.G.; Porsteinsson, A.P.; Rabins, P.V.; Rosenberg, P.B.; Schneider, L.S.; Shade, D.M.; Weintraub, D.; Yesavage, J.; Lyketsos, C.G. CitAD Research Group. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One 2014, 9(6), e98426. https://doi.org/10.1371/journal.pone.0098426.

107

Ray, W.A.; Chung, C.P.; Murray, K.T.; Hall, K.; Stein, C.M. High-dose citalopram and escitalopram and the risk of out-of-hospital death. J Clin Psychiatry 2017, 78(2), 190-195. https://doi.org/10.4088/JCP.15m10324.

108

Suzuki, Y.; Tajiri, M.; Sugimoto, A.; Orime, N.; Hayashi, T.; Egawa, J.; Sugai, T.; Inoue, Y.; Someya, T. Sex differences in the effect of atomoxetine on the QT interval in adult patients with attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2017, 37(1), 27-31. https://doi.org/10.1097/JCP.0000000000000630.

109

van Noord, C.; Dörr, M.; Sturkenboom, M.C.; Straus, S.M.; Reffelmann, T.; Felix, S.B.; Hofman, A.; Kors, J.A.; Haring, R.; de Jong, F.H.; Nauck, M.; Uitterlinden, A.G.; Wallaschofski, H.; Witteman, J.C.; Völzke, H.; Stricker, B.H. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol. 2010, 25(1), 21-8. https://doi.org/10.1007/s10654-009-9406-z.

110

Scherer, D.; Hassel, D.; Bloehs, R.; Zitron, E.; von Löwenstern, K.; Seyler, C.; Thomas, D.; Konrad, F.; Bürgers, H.F.; Seemann, G.; Rottbauer, W.; Katus, H.A.; Karle, C.A.; Scholz, E.P. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol. 2009, 156(2), 226-36. https://doi.org/10.1111/j.1476-5381.2008.00018.x.

111

Reed, V.A.; Buitelaar, J.K.; Anand, E.; Day, K.A.; Treuer, T.; Upadhyaya, H.P.; Coghill, D.R.; Kryzhanovskaya, L.A.; Savill, N.C. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a recade of research. CNS Drugs 2016, 30(7), 603-28. https://doi.org/10.1007/s40263-016-0349-0.

112

Nasser, A.; Faison, S.L.; Liranso, T.; Adewole, T.; Busse, G.D.; Fava, M.; Kleiman, R.B.; Schwabe, S. Evaluation of the effect of SPN-812 (viloxazine extended-release) on QTc interval in healthy adults. J Clin Psychiatry 2020, 81(6), 20m13395. https://doi.org/10.4088/JCP.20m13395.

113

Jasiak, N.M.; Bostwick, J.R. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014, 48(12), 1620-8. https://doi.org/10.1177/1060028014550645.

114

Caillier, B.; Pilote, S.; Castonguay, A.; Patoine, D.; Ménard-Desrosiers, V.; Vigneault, P.; Hreiche, R.; Turgeon, J.; Daleau, P.; De Koninck, Y.; Simard, C.; Drolet, B. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile. Fundam Clin Pharmacol. 2012, 26(5), 599-608. https://doi.org/10.1111/j.1472-8206.2011.00953.x.

115

Mago, R.; Forero, G.; Greenberg, W.M.; Gommoll, C.; Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013, 33(10), 761-71. https://doi.org/10.1007/s40261-013-0126-5.

116

Huang, Q.; Zhong, X.; Yun, Y.; Yu, B.; Huang, Y. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2016, 12, 2707–2714. https://doi.org/10.2147/NDT.S114955.

117

Isbister, G.K.; Polanski, R.; Cooper, J.M.; Keegan, M.; Isoardi, K.Z. Duloxetine overdose causes sympathomimetic and serotonin toxicity without major complications. Clin Toxicol (Phila). 2022, 60(9), 1019-1023. https://doi.org/10.1080/15563650.2022.2083631.

118

Behlke, L.M.; Lenze, E.J.; Carney, R.M. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs 2020, 34(11), 1133-1147. https://doi.org/10.1007/s40263-020-00763-z.

119

Waring, W.S. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf. 2012, 4, 93-101. https://doi.org/10.2147/DHPS.S28804.

120

Scott, L.J. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder. CNS Drugs 2014, 28(11), 1071–1082. https://doi.org/10.1007/s40263-014-0203-1.

121

Colvard, M.D. Key differences between Venlafaxine XR and Desvenlafaxine: An analysis of pharmacokinetic and clinical data. Mental Health Clinician 2014, 4(1), 35–39 https://doi.org/10.9740/mhc.n186977.

122

Allen, N.D.; Leung, J.G.; Palmer, B.A. Mirtazapine's effect on the QT interval in medically hospitalized patients. Ment Health Clin. 2020, 10(1), 30-33. https://doi.org/10.9740/mhc.2020.01.030.

123

Gurkan, S.; Liu, F.; Chain, A.; Gutstein, D.E. A study to assess the proarrhythmic potential of mirtazapine using concentration-QTc (C-QTc) analysis. Clin Pharmacol Drug Dev. 2019, 8(4), 449-458. https://doi.org/10.1002/cpdd.605.

124

Mohan, G.; Ajitkumar, A.; Bhide, P.; Ravilla, J.; Kramer, V. Trazodone overdose manifesting as hypotension and QT prolongation. Cureus 2023, 15(3), e36871. https://doi.org/10.7759/cureus.36871.

125

Matsuda, Y.; Furukawa, Y.; Yamazaki, R.; Inamura, K.; Kito, S.; Nunomura, A.; Shigeta, M. Mirtazapine-induced long QT syndrome in an elderly patient: a case report. Psychogeriatrics 2020, 20(4), 536-537. https://doi.org/10.1111/psyg.12520.

126

Armstrong, S.E.M.; Brown, H.K.; Shorey, C.; Madan, R.; Szabuniewicz, C.; Koh, S.; Crépeau-Gendron, G.; Mah, L. No association between trazodone and corrected-QT prolongation in older adults. J Clin Psychopharmacol. 2019, 39(5), 528-530. https://doi.org/10.1097/JCP.0000000000001102.

127

Donazzolo, Y.; Latreille, M.; Caillaud, M.A.; Mocaer, E.; Seguin, L. Evaluation of the effects of therapeutic and supratherapeutic doses of agomelatine on the QT/QTc interval: a phase I, randomized, double-blind, placebo-controlled and positive-controlled, crossover thorough QT/QTc study conducted in healthy volunteers. J Cardiovasc Pharmacol. 2014, 64(5), 440-51. https://doi.org/10.1097/FJC.0000000000000136.

128

Heun, R.; Ahokas, A.; Boyer, P.; Giménez-Montesinos, N.; Pontes-Soares, F.; Olivier, V. Agomelatine study group. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 2013, 74(6), 587-94. https://doi.org/10.4088/JCP.12m08250.

129

Tellone, V.; Rosignoli, M.T.; Picollo, R.; Dragone, P.; Del Vecchio, A.; Comandini, A.; Radicioni, M.; Leuratti, C.; Calisti, F. Effect of 3 single doses of trazodone on QTc interval in healthy subjects. J Clin Pharmacol. 2020, 60(11), 1483-1495. https://doi.org/10.1002/jcph.1640.

130

Scherer, D.; von Löwenstern, K.; Zitron, E.; Scholz, E.P.; Bloehs, R.; Kathöfer, S.; Thomas, D.; Bauer, A.; Katus, H.A.; Karle, C.A.; Kiesecker, C. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch Pharmacol. 2008, 378(1), 73-83. https://doi.org/10.1007/s00210-008-0289-4.

131

Danielsson, B.; Collin, J.; Jonasdottir Bergman, G.; Borg, N.; Salmi, P.; Fastbom, J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol. 2016, 81(4), 773-83. https://doi.org/10.1111/bcp.12829.

132

Lee, S.; Lee, H.A.; Kim, S.J.; Kim, K.S. Cellular mechanisms for trazodone-induced cardiotoxicity. Hum Exp Toxicol. 2016, 35(5), 501-10. https://doi.org/10.1177/0960327115595683.

133

Soe, K.K.; Lee, M.Y. Arrhythmias in severe trazodone overdose. Am J Case Rep. 2019, 20, 1949-1955. https://doi.org/ 10.12659/AJCR.919833.

134

Saiz-Rodríguez, M.; Belmonte, C.; Derqui-Fernández, N.; Cabaleiro, T.; Román, M.; Ochoa, D.; Talegón, M.; Ovejero-Benito, M.C.; Abad-Santos, F. Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. Pharmacogenomics 2017, 18(16), 1491-1502. https://doi.org/10.2217/pgs-2017-0116.

135

Husak, N.; Leonard, J.B.; Seung, H.; Klein-Schwartz, W. Single-substance trazodone exposures reported to US poison centers from 2000 to 2019. Clin Toxicol (Phila). 2022, 60(9), 1032-1038. https://doi.org/10.1080/15563650.2022.2068423.

136

Sahli, Z.T.; Banerjee, P.; Tarazi, F.I. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov. 2016, 11(5), 515–523. https://doi.org/10.1517/17460441.2016.1160051.

137

Lee, S.; Lee, H.A.; Choi, S.W.; Kim, S.J.; Kim, K.S. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016, 296, 42-53. https://doi.org/10.1016/j.taap.2016.01.015.

138

Connolly, K.R.; Thase, M.E. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother. 2016, 17(3), 421–431. https://doi.org/10.1517/14656566.2016.1133588.

139

Bordet, C.; Rousseau, V.; Montastruc, F.; Montastruc, J.L. QT prolongation and vortioxetine: a post-marketing study and comparison with other serotonin reuptake inhibitors. Psychopharmacology (Berl). 2020, 237(4), 1245-1247. https://doi.org/10.1007/s00213-020-05461-8.

140

Wang, Y.; Nomikos, G.G.; Karim, A.; Munsaka, M.; Serenko, M.; Liosatos, M.; Harris, S. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2013, 2(4), 298-309. https://doi.org/10.1002/cpdd.51.

141

Filippova, N.V.; Barylnik, Yu.B.; Bogdanova, T.M.; Blinova, V.V.; Shchelchkova, A.A.; Mozgacheva, E.S. Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients. V.M. Bekhterev review of psychiatry and medical psychology 2023, 57(2), 105-115. https://doi.org/10.31363/2313-7053-2023-817.

142

Lauschke, V.M.; Ingelman-Sundberg, M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019, 130, 65–77. https://doi.org/10.1016/j.ejps.2019.01.024.

143

Lauschke, V.M.; Zhou, Y.; Ingelman-Sundberg, M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019, 197, 122–52. https://doi.org/10.1016/j.pharmthera.2019.01.002.

144

van Westrhenen, R.; Aitchison, K.J.; Ingelman-Sundberg, M.; Jukić, M.M. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front. Psychiatry. 2020, 11, 94. https://doi.org/10.3389/fpsyt.2020.00094.

145

Hauser, A.S; Chavali, S.; Masuho, I.; Jahn, L.J.; Martemyanov, K.A.; Gloriam, D.E.; Babu, M.M. Pharmacogenomics of GPCR drug targets. Cell. 2018, 172(1-2), 41–54 e19. https://doi.org/10.1016/j.cell.2017.11.033.

146

Zeier, Z.; Carpenter, L.L.; Kalin, N.H.; Rodriguez, C.I.; McDonald, W.M.; Widge, A.S.; Nemeroff, C.B. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018, 175(9), 873–86. https://doi.org/10.1176/appi.ajp.2018.17111282.

147

Clinical Pharmacogenetics Implementation Consortium (CPIC); 2009-. Guidelines. [Updated 2022 Sep 23]. [Accessed June 28, 2023]. Available at: https://cpicpgx.org/guidelines/.

148

Nasyrova, R.F.; Neznanov, N.G.; editors. Clinical Psychopharmacogenetics. DEAN Publishing House; Saint-Petersburg, Russia: 2019. 405p. ISBN 978-5-6043573-7-8.

149

Crisafulli, C.; Fabbri, C.; Porcelli, S.; Drago, A.; Spina, E.; De Ronchi, D.; Serretti, A. Pharmacogenetics of antidepressants. Front Pharmacol. 2011, 16, 2, 6. https://doi.org/10.3389/fphar.2011.00006.

150

Tanaka, E. Toxicological interactions involving psychiatric drugs and alcohol: an update. J Clin Pharm Ther. 2003, 28(2), 81-95. https://doi.org/10.1046/j.1365-2710.2003.00459.x.

151

Menkes, D.B.; Herxheimer, A. Interaction between antidepressants and alcohol: signal amplification by multiple case reports. Int J Risk Saf Med. 2014, 26(3), 163-70. https://doi.org/10.3233/JRS-140632.

152

Oliveira, P.; Ribeiro, J.; Donato, H.; Madeira, N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry 2017, 16, 17. https://doi.org/10.1186/s12991-017-0140-8.

153

Maideen, N.M.P. Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine. World J Pharmacol. 2019, 8(2), 14-25. https://doi.org/10.5497/wjp.v8.i2.14.

154

Bousman, C.A.; Bengesser, S.A.; Aitchison, K.J.; Amare, A.T.; Aschauer, H.; Baune, B.T.; Asl, B.B.; Bishop, J.R.; Burmeister, M.; Chaumette, B.; Chen, L.S.; Cordner, Z.A.; Deckert, J.; Degenhardt, F.; DeLisi, L.E.; Folkersen, L.; Kennedy, J.L.; Klein, T.E.; McClay, J.L.; McMahon, F.J.; Musil, R.; Saccone, N.L.; Sangkuhl, K.; Stowe, R.M.; Tan, E.C.; Tiwari, A.K.; Zai, C.C.; Zai, G.; Zhang, J.; Gaedigk, A.; Müller, D.J. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry. 2021, 54(1), 5-17. https://doi.org/10.1055/a-1288-1061.

155

Bousman, C.A.; Forbes, M.; Jayaram, M.; Eyre, H.; Reynolds, C.F.; Berk, M.; Hopwood, M.; Ng, C. Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry. 2017, 17(1), 60. https://doi.org/10.1186/s12888-017-1230-5.

156

Thompson, C.; Steven, P.H.; Catriona, H. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res. 2015, 226(1), 68–72. https://doi.org/10.1016/j.psychres.2014.11.044.

157

Salm, M.; Abbate, K.; Appelbaum, P.; Ottman, R.; Chung, W.; Marder, K.; Leu, C.S.; Alcalay, R.; Goldman, J.; Curtis, A.M.; Leech, C.; Taber, K.J.; Klitzman, R. Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training. J Genet Couns. 2014, 23(2), 156–63. https://doi.org/10.1007/s10897-013-9624-0.

158

Bousman, C.A.; Hopwood, M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016, 3(6), 585–90. https://doi.org/10.1016/S2215-0366(16)00017-1.

159

The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document) Available at: http://www.cebm.net/index.aspx?o=5653.

160

Peterson, K.; Dieperink, E.; Anderson, J.; Boundy, E.; Ferguson, L.; Helfand, M. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology (Berl). 2017, 234(11), 1649-1661. https://doi.org/10.1007/s00213-017-4622-9.

161

Rosenblat, J.D.; Lee, Y.; McIntyre, R.S. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. J Clin Psychiatry. 2017, https://doi.org/10.4088/JCP.15r10583.

162

Fricke-Galindo, I.; Cespedes-Garro, C.; Rodrigues-Soares, F.; Naranjo, M.E.; Delgado, A.; de Andres, F.; Lopez-Lopez, M.; Penas-Lledo, E.; LLerena, A. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016, 16(2), 113–23. https://doi.org/10.1038/tpj.2015.70.

163

Gaedigk, A.; Sangkuhl, K.; Whirl-Carrillo, M.; Klein, T.; Leeder, J.S. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017, 19(1), 9-76. https://doi.org/10.1038/gim.2016.80.

164

Mizzi, C.; Dalabira, E.; Kumuthini, J.; Dzimiri, N.; Balogh, I.; Basak, N.; Bohm, R.; Borg, J.; Borgiani, P.; Bozina, N.; Bruckmueller, H.; Burzynska, B.; Carracedo, A.; Cascorbi, I.; Deltas, C.; Dolzan, V.; Fenech, A.; Grech, G.; Kasiulevicius, V.; Kádaši, Ľ.; Kučinskas, V.; Khusnutdinova, E.; Loukas, Y.L.; Macek, M.Jr.; Makukh, H.; Mathijssen, R.; Mitropoulos, K.; Mitropoulou, C.; Novelli, G.; Papantoni, I.; Pavlovic, S.; Saglio, G.; Setric, J.; Stojiljkovic, M.; Stubbs, A.P.; Squassina, A.; Torres, M.; Turnovec, M.; van Schaik, R.H.; Voskarides, K.; Wakil, S.M.; Werk, A.; Del Zompo, M.; Zukic, B.; Katsila, T.; Lee, M.T.; Motsinger-Rief, A.; Mc Leod, H.L.; van der Spek, P.J.; Patrinos, G.P. A european spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One. 2016, 11(9), e0162866. https://doi.org/10.1371/journal.pone.0162866.

165

Singh, A.B. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015, 13(2), 150–6. https://doi.org/10.9758/cpn.2015.13.2.150.

166

Hall-Flavin, D.K.; Winner, J.G.; Allen, J.D.; Carhart, J.M.; Proctor, B.; Snyder, K.A.; Drews, M.S.; Eisterhold, L.L.; Geske, J.; Mrazek, D.A. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013, 23(10), 535–48. https://doi.org/10.1097/FPC.0b013e3283649b9a.

167

Breitenstein, B.; Scheuer, S.; Pfister, H.; Uhr, M.; Lucae, S.; Holsboer, F.; Ising, M.; Bruckl, T.M. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr. 2014, 19(2), 165–75. https://doi.org/10.1017/S1092852913000436.

168

Brennan, F.X.; Gardner, K.R.; Lombard, J.; Perlis, R.H.; Fava, M.; Harris, H.W.; Scott, R. A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. Prim Care Companion CNS Disord. 2015, 17(2), 10.4088/PCC.14m01717. https://doi.org/10.4088/PCC.14m01717.

169

Winner, J.; Allen, J.D.; Altar, C.A.; Spahic-Mihajlovic, A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013, 3:e242. https://doi.org/10.1038/tp.2013.2.

170

Winner, J.G.; Carhart, J.M.; Altar, C.A.; Goldfarb, S.; Allen, J.D.; Lavezzari, G.; Parsons, K.K.; Marshak, A.G.; Garavaglia, S.; Dechairo, B.M. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015, 31(9), 1633–43. https://doi.org/10.1185/03007995.2015.1063483.

171

Brixner, D.; Biltaji, E.; Bress, A.; Unni, S.; Ye, X.; Mamiya, T.; Ashcraft, K.; Biskupiak, J. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016, 19(3), 213–28. https://doi.org/10.3111/13696998.2015.1110160.

172

Roberts, J.D.; Wells, G.A.; Le May, M.R.; Labinaz, M.; Glover, C.; Froeschl, M.; Dick, A.; Marquis, J.F.; O’Brien, E.; Goncalves, S.; Druce, I.; Stewart, A.; Gollob, M.H. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012, 379(9827), 1705–11. https://doi.org/10.1016/S0140-6736(12)60161-5.

173

Hudson, K.L.; Holohan, M.K.; Collins, F.S. Keeping pace with the times–the genetic information nondiscrimination Act of 2008. N Engl J Med. 2008, 358(25), 2661–3. https://doi.org/10.1056/NEJMp0803964.

174

Haga, S.B.; O’Daniel, J.M.; Tindall, G.M.; Lipkus, I.R.; Agans, R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 2012, 12(3), 197–204. https://doi.org/10.1038/tpj.2011.1.

175

Lanktree, M.B.; Zai, G.; Vanderbeek, L.E.; Giuffra, D.E.; Smithson, D.S.; Kipp, L.B.; Dalseg, T.R.; Speechley, M.; Kennedy, J.L. Positive perception of pharmacogenetic testing for psychotropic medications. Hum Psychopharmacol. 2014, 29(3), 287–91. https://doi.org/10.1002/hup.2383.

176

Reddy, A.P.; Sawant, N.; Morton, H.; Kshirsagar, S.; Bunquin, L.E.; Yin, X.; Reddy, P.H. Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer’s disease. Human Molecular Genetics 2021, 30(9), 789–810. https://doi.org/10.1093/hmg/ddab091.

177

Zhang, Q.; Yang, C.; Liu, T.; Liu, L.; Li, F.; Cai, Y.; Fan, X. Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer’s disease-like pathology. Neuropharmacology 2018, 131, 475–486. https://doi.org/10.1016/j.neuropharm.2017.12.

178

Henry, M.E.; Schmidt, M.E.; Hennen, J.; Villafuerte, R.A.; Butman, M.L.; Tran, P.; Kerner, L.T.; Cohen, B.; Renshaw, P.F. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology. 2005, 30, 1576-1583. https://doi.org/10.1038/sj.npp.1300749.

179

Medicines and Healthcare Products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation: new maximum daily dose restrictions (including in elderly patients), contraindications and warnings. Accessed March 23, 2013. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769.

180

Nikitina, A.Yu.; Levin, O.S. A The use of trazodone in neuropsychiatric disorders in the elderly. Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders] 2022, 4, 43–48. https://doi.org/10.21265/PSYPH.2022.60.29.006.

181

Danilov, D.S.; Mul'timodal'nye serotoninergicheskie antidepressanty [Multimodal serotonergic antidepressants]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017, 117(9), 103-111. https://doi.org/10.17116/jnevro201711791103-111.

182

FDA. Medication Guides. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page&utm_campaign=SBIA%3A%20FDA%20Launches%20New%20Medication%20Guide%20Data-base&utm_medium=email&utm_source=Eloqua.

183

OMIM Online Mendelian Inheritance in Man. An Online Catalog of Human Genes and Genetic Disorders. [Updated 3 September 2021] [accessed on 10 February 2022]. Available at: https://www.omim.org/.

184

Bonnet, U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003, 9(1), 97-140. https://doi.org/10.1111/j.1527-3458.2003.tb00245.x.

185

Shnayder, N.A.; Grechkina, V.V.; Khasanova, A.K.; Bochanova, E.N.; Dontceva, E.A.; Petrova, M.M.; Asadullin, A.R.; Shipulin, G.A.; Altynbekov, K.S.; Al-Zamil, M.; Nasyrova R.F. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023, 13, 134. https://doi.org/10.3390/metabo13010134.

186

FDA. Medication Guides. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021336s014lbl.pdf#page=34.

187

Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001, 27(4), 383-91. https://doi.org/10.1038/86882.

188

Hustert, E.; Haberl, M.; Burk, O.; Wolbold, R.; He, Y.Q,; Klein, K.; Nuessler, A.C.; Neuhaus, P.; Klattig, J.; Eiselt, R.; Koch, I.; Zibat, A.; Brockmöller, J.; Halpert, J.R.; Zanger, U.M.; Wojnowski, L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001, 11(9), 773-9. https://doi.org/10.1097/00008571-200112000-00005.

189

Hicks, J.K.; Sangkuhl, K.; Swen, J.J.; Ellingrod, V.L.; Müller, D.J.; Shimoda, K.; Bishop, J.R.; Kharasch, E.D.; Skaar, T.C.; Gaedigk, A.; Dunnenberger, H.M.; Klein, T.E.; Caudle, K.E.; Stingl, J.C. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017, 102(1), 37-44. https://doi.org/10.1002/cpt.597.

190

Matthaei, J.; Brockmöller, J.; Steimer, W.; Pischa, K.; Leucht, S.; Kullmann, M.; Jensen, O.; Ouethy, T.; Tzvetkov, M.V.; Rafehi, M. Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmaco-kinetics in Healthy Volunteers and Depressive Disorder Patients. Front Pharmacol. 2021, 12, 688950. https://doi.org/10.3389/fphar.2021.688950.

191

The Pharmacogene Variation (PharmVar) Consortium. Updated 2017 Available at: https://www.pharmvar.org/gene/CYP1A2.

192

dbSNP Short Genetic Variations. Updated September 21, 2022 Available at: https://www.ncbi.nlm.nih.gov/snp/rs2069514.

193

Bousman, C.A.; Stevenson, J.M.; Ramsey, L.B.; Sangkuhl, K.; Hicks, J.K.; Strawn, J.R.; Singh, A.B.; Ruaño, G.; Mueller, D.J.; Tsermpini, E.E.; Brown, J.T.; Bell, G.C.; Leeder, J.S.; Gaedigk, A.; Scott, S.A.; Klein, T.E.; Caudle, K.E.; Bishop, J.R. Clinical Pharmaco-genetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023, 114(1), 51-68. https://doi.org/10.1002/cpt.2903.

194

Brown, J.T.; Bishop, J.R.; Sangkuhl, K.; Nurmi, E.L.; Mueller, D.J.; Dinh, J.C.; Gaedigk, A.; Klein, T.E.; Caudle, K.E.; McCracken, J.T.; de Leon, J.; Leeder, J.S. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019, 106(1), 94-102. https://doi.org/10.1002/cpt.1409.

195

Calleja, S.; Zubiaur, P.; Ochoa, D.; Villapalos-Garcia, G.; Mejia-Abril, G.; Soria-Chacartegui, P.; Navares-Gomez, M.; de Miguel, A.; Roman, M.; Martin-Vilchez, S.; Abad-Santos, F. Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine. Front Pharmacol. 2023, 2, 14:1110460. https://doi.org/10.3389/fphar.2023.1110460.

196

Bagher, A.M. Association of CYP2C9∗3 and CYP2C8∗3 Non-Functional Alleles with Ibuprofen-Induced Upper Gastrointestinal Toxicity in a Saudi Patient. Case Rep Med. 2023, 6623269. https://doi.org/10.1155/2023/6623269.

197

Sandosh Padmanabhan. Handbook of Pharmacogenomics and Stratified Medicine. 2014. ISBN978-0-12-386882-4 https://doi.org/10.1016/C2010-0-67325-1.

198

King, L.M.; Ma, J.; Srettabunjong, S.; Graves, J.; Bradbury, J.A.; Li, L.; Spiecker, M.; Liao, J.K.; Mohrenweiser, H.; Zeldin, D.C. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol. 2002, 61(4), 840-52. https://doi.org/10.1124/mol.61.4.840.

199

Bruno, A.; Morabito, P.; Spina, E.; Muscatello, M.R. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol. 2016, 14(2), 191-9. PubMed ID 26572745.

200

Timmer, C.J.; Sitsen, J.M.; Delbressine, L.P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000, 38(6), 461-74. https://doi.org/10.2165/00003088-200038060-00001.

201

Chavan, B.B.; Kalariya, P.D.; Tiwari, S.; Nimbalkar, R.D.; Garg, P.; Srinivas, R.; Talluri, M.V.N.K. Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom. 2017, 31(23), 1974-1984. https://doi.org/10.1002/rcm.7982.

202

Yu, C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020, 50(11), 1285-1300. https://doi.org/10.1080/00498254.2020.1767319.

The authors declare that there are no conflicts of interest present.